Xiromed debuts generic Nitropress
The medication is used to treat the symptoms of acute heart failure, hypertensive crisis and controlled hypotension during surgery.
Xiromed is introducing sodium nitroprusside injection, in a dosage strength of 50 mg/2 mL (25 mg/mL).
The medication is the generic of Nitropress.
[Read more: Xiromed unveils generic Extina]
It is used to treat the symptoms of acute heart failure, hypertensive crisis and controlled hypotension during surgery.
“The launch of sodium nitroprusside injection is Xiromed’s latest offering from our pipeline of injectable products and demonstrates our commitment to providing value to our institutional customers,” Narasimhan Mani, Xiromed CEO, said.
[Read more: Xiromed launches generic Prilosec]
Nitropress and its generics had a market value of $3.7 million, for the 12 months ending November 2021, according to IQVIA.